The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer

被引:29
|
作者
Schwede, Matthew [1 ]
Waldron, Levi [2 ]
Mok, Samuel C. [3 ]
Wei, Wei [4 ]
Basunia, Azfar [1 ,5 ]
Merritt, Melissa A. [6 ]
Mitsiades, Constantine S. [7 ]
Parmigiani, Giovanni [1 ,5 ]
Harrington, David P. [1 ,5 ]
Quackenbush, John [5 ]
Birrer, Michael J. [8 ]
Culhane, Aedin C. [1 ,5 ]
机构
[1] Dana Farber Canc Inst, Dept Data Sci, Boston, MA 02115 USA
[2] CUNY, Grad Sch Publ Hlth & Hlth Policy, Biostat, New York, NY 10021 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA
[4] Pfizer, Andover, MA USA
[5] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA
[6] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA
[7] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[8] Univ Alabama Birmingham, Div Hematol Oncol, Birmingham, AL USA
关键词
BREAST-CANCER; TUMOR-STROMA; METASTASIS; DISCOVERY; SUMMARIES; SURVIVAL; GRADE;
D O I
10.1158/1055-9965.EPI-18-1359
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Recent efforts to improve outcomes for high-grade serous ovarian cancer, a leading cause of cancer death in women, have focused on identifying molecular subtypes and prognostic gene signatures, but existing subtypes have poor cross-study robustness. We tested the contribution of cell admixture in published ovarian cancer molecular subtypes and prognostic gene signatures. Methods: Gene signatures of tumor and stroma were developed using paired microdissected tissue from two independent studies. Stromal genes were investigated in two molecular subtype classifications and 61 published gene signatures. Prognostic performance of gene signatures of stromal admixture was evaluated in 2,527 ovarian tumors (16 studies). Computational simulations of increasing stromal cell proportion were performed by mixing geneexpression profiles of paired microdissected ovarian tumor and stroma. Results: Recently described ovarian cancer molecular subtypes are strongly associated with the cell admixture. Tumors were classified as different molecular subtypes in simulations where the percentage of stromal cells increased. Stromal gene expression in bulk tumors was associated with overall survival (hazard ratio, 1.17; 95% confidence interval, 1.11-1.23), and in one data set, increased stroma was associated with anatomic sampling location. Five published prognostic gene signatures were no longer prognostic in a multivariate model that adjusted for stromal content. Conclusions: Cell admixture affects the interpretation and reproduction of ovarian cancer molecular subtypes and gene signatures derived from bulk tissue. Elucidating the role of stroma in the tumor microenvironment and in prognosis is important. Impact: Single-cell analyses may be required to refine the molecular subtypes of high-grade serous ovarian cancer.
引用
收藏
页码:509 / 519
页数:11
相关论文
共 50 条
  • [31] Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma
    Gilks, C. Blake
    JOURNAL OF ONCOLOGY, 2010, 2010
  • [32] PROGNOSTIC SIGNATURES OF BREAST CANCER: PEROU'S MOLECULAR SUBTYPES AND SCHMIDT'S METAGENES
    Cadenas, Cristina
    EXCLI JOURNAL, 2012, 11 : 204 - 207
  • [33] Classification of molecular subtypes of high-grade serous ovarian cancer by MALDI-Imaging.
    Kassuhn, Wanja Nikolai
    Klein, Oliver
    Darb-Esfahani, Silvia
    Lammert, Hedwig
    Handzik, Sylwia
    Taube, Eliane T.
    Schmitt, Wolfgang D.
    Dorigo, Oliver
    Horst, David
    Keunecke, Carlotta
    Dreher, Felix
    George, Joshy
    Bowtell, David
    Hummel, Michael
    Sehouli, Jalid
    Bluethgen, Nils
    Kulbe, Hagen
    Braicu, Elena Ioana
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging
    Kassuhn, Wanja
    Klein, Oliver
    Darb-Esfahani, Silvia
    Lammert, Hedwig
    Handzik, Sylwia
    Taube, Eliane T.
    Schmitt, Wolfgang D.
    Keunecke, Carlotta
    Horst, David
    Dreher, Felix
    George, Joshy
    Bowtell, David D.
    Dorigo, Oliver
    Hummel, Michael
    Sehouli, Jalid
    Bluthgen, Nils
    Kulbe, Hagen
    Braicu, Elena I.
    CANCERS, 2021, 13 (07)
  • [35] Chemoresistance in high grade serous ovarian cancer molecular subtypes and the role of NRF2
    Toma, Helen
    Al-Odat, Omar S.
    Hamad, Layla
    Joshi, Hansa
    Kelly, Rebeca
    Katz, Chelsea
    Shojaei, Hadi
    Li, Yahui
    Mitra, Ramkrishna
    Bendjilali, Nasrine
    Spitz, Francis R.
    Chu, Christina
    Krill, Lauren
    Pandey, Manoj
    Wang, Yemin
    Warshal, David Philip
    Hamad, Samera
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] THE PROGNOSTIC IMPACT OF NANOG EXPRESSION IN OVARIAN SEROUS CARCINOMA
    Suster, N. Kenda
    Smrkolj, S.
    Virant-Klun, I.
    Grazio, S. Frkovic
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1672 - 1672
  • [37] THE PROGNOSTIC IMPACT OF NANOG EXPRESSION IN OVARIAN SEROUS CARCINOMA
    Suster, N. Kenda
    Smrkolj, S.
    Virant-Klun, I.
    Grazio, S. Frkovic
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 535 - 535
  • [38] Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer
    Shibai Yan
    Juntao Fang
    Yongcai Chen
    Yong Xie
    Siyou Zhang
    Xiaohui Zhu
    Feng Fang
    BMC Cancer, 20
  • [39] Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer
    Yan, Shibai
    Fang, Juntao
    Chen, Yongcai
    Xie, Yong
    Zhang, Siyou
    Zhu, Xiaohui
    Fang, Feng
    BMC CANCER, 2020, 20 (01)
  • [40] DNA methylation markers associated with serous ovarian cancer subtypes
    Chandavarkar, U.
    Campan, M.
    Houshdaran, S.
    Pearce, C.
    Shen, H.
    Widschwendter, M.
    Berchuck, A.
    Roman, L.
    Laird, P.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S48 - S48